The Effect of Quercetin in Sarcoidosis

This study has been completed.
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00402623
First received: November 20, 2006
Last updated: February 21, 2008
Last verified: February 2008

November 20, 2006
February 21, 2008
January 2006
January 2006   (final data collection date for primary outcome measure)
  • antioxidant status after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • inflammatory status after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • antioxidant status after 24 hours
  • inflammatory status after 24 hours
Complete list of historical versions of study NCT00402623 on ClinicalTrials.gov Archive Site
  • plasma quercetin concentration after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • plasma malondialdehyde (MDA) levels after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • plasma quercetin concentration after 24 hours
  • plasma malondialdehyde (MDA) levels after 24 hours
Not Provided
Not Provided
 
The Effect of Quercetin in Sarcoidosis
The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Sarcoidosis
  • Dietary Supplement: quercetin
    1000 mg quercetin within 24 hours
  • Other: placebo
  • Placebo Comparator: 1
    placebo
    Intervention: Other: placebo
  • Active Comparator: 2
    quercetin (food supplement)
    Intervention: Dietary Supplement: quercetin
Boots AW, Drent M, de Boer VC, Bast A, Haenen GR. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr. 2011 Aug;30(4):506-12. doi: 10.1016/j.clnu.2011.01.010. Epub 2011 Feb 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
January 2006
January 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
  • no smoking
  • no treatment

Exclusion Criteria:

  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  • use of food supplements or vitamins
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00402623
MEC 05.142.5
No
Dr. A.W. Boots, Maastricht University
Maastricht University
ZonMw: The Netherlands Organisation for Health Research and Development
Study Chair: Aalt Bast, PhD Maastricht University
Principal Investigator: Agnes W Boots, PhD Maastricht University
Study Director: Guido R Haenen, PhD Maastricht University
Maastricht University Medical Center
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP